Infliximab vs adalimumab in gastric CD
Does infliximab achieve higher endoscopic remission rates at 12 months than adalimumab in patients with gastric CD
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
no head-to-head data isolate infliximab vs adalimumab for endoscopic remission at 12 months in gastric/gastroduodenal Crohn's, the retrieved evidence reports the two agents only pooled or in unrelated postoperative and small-bowel settings. In gastroduodenal CD the only cited comparison is a prospective series where 72.7% of patients treated with infliximab or adalimumab (grouped together) achieved mucosal healing at 12 weeks vs 12.5% on conventional therapy. The drugs are not separated and the timepoint is 12 weeks, not 12 months 1. 1–3
What is known:
- In gastroduodenal CD, a prospective trial reported mucosal healing at 12 weeks in 72.7% of patients on infliximab or adalimumab (pooled) vs 12.5% on conventional therapy, no per-drug breakdown. 1
- A retrospective real-world CD cohort found no significant difference between infliximab and adalimumab groups in event-free, retention, dose-escalation-free, or surgery-free rates. 2
- The 12-month endoscopic remission figures in the corpus (78.6% infliximab vs 18.8% control) come from a postoperative ileocolonic-resection RCT, not a gastric-CD infliximab-vs-adalimumab comparison. 3
What is unknown / caveats:
- No gastric-CD study separates infliximab from adalimumab
- Gastroduodenal data are 12-week mucosal healing, not 12-month endoscopic remission
- Controlled data for upper-GI CD therapy are essentially absent
- The corpus contains no direct infliximab-vs-adalimumab endoscopic-remission comparison in gastric Crohn's at any timepoint.
References
- Miranda CJ, Ali MH, Ayaz M, Soofi Y, Mahl TC. An Obscure Presence of Gastroduodenal Involvement in a Newly Diagnosed Ileocolonic Crohn's Disease Patient. Case Rep Gastrointest Med. 2022. PMID: 37250849.
- Otake H, Matsumoto S, Mashima H. Long-term clinical and real-world experience with Crohn's disease treated with anti-tumor necrosis factor-α antibodies. Intest Res. 2022. PMID: 35350094.
- Yamamoto T, Watanabe T. Surgery for luminal Crohn's disease. World J Gastroenterol. 2014;20(1):78-90. PMID: 24415860.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.
Reviewer notes